Oncolytics Biotech (ONCY)
NASDAQ:ONCY
Want to see ONCY full AI Analyst Report?
ONCY Stock Chart & Stats
$1.12
-$0.03(-3.70%)
At close: 4:00 PM EST
$1.12
-$0.03(-3.70%)
Day’s Range― - ―
52-Week Range$0.33 - $1.51
Previous CloseN/A
Volume216.96K
Average Volume (3M)878.77K
Market Cap
$112.49M
Enterprise Value$119.04M
Total Cash (Recent Filing)$5.20M
Total Debt (Recent Filing)$563.00K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding116,128,160
10 Day Avg. Volume1,168,510
30 Day Avg. Volume878,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-4.17
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.14
Forecast
1Y Price Target
$6.00Price Target Upside435.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Validation StrategyFast Track designation and a planned randomized study testing pelareorep with standard therapy in hard-to-treat microsatellite-stable, KRAS-mutant colorectal cancer increase the likelihood of generating confirmatory data that could support broader label expansion.
Delivery And Immune MechanismIntravenous administration coupled with observed tumor-directed immune activation and increased T-cell infiltration supports potential use across metastatic tumors and as a partner to checkpoint inhibitor therapies.
Regulatory PathwayPlanned engagement with the U.S. Food and Drug Administration, including a Type C meeting and discussion of a single-arm accelerated approval pathway, creates a clearer route toward potential registration in a rare anal cancer population without approved treatments.
Bears Say
Competitive And Reimbursement RiskCompetition from other immuno-oncology approaches and uncertain reimbursement dynamics for a new oncolytic therapy may limit commercial uptake even if pivotal trials are positive.
Data Robustness And Validation RiskEfficacy signals are based on small, heavily pretreated patient cohorts, leaving substantial uncertainty until findings are reproduced in larger, controlled registration trials.
Financing And Dilution RiskAnticipated equity raises to support ongoing clinical development could dilute existing shareholders and weigh on the stock before late-stage data or regulatory milestones are achieved.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.33 and its highest was $1.51 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $112.49M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is May 01, 2026 which is in 2 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Mar 30, 2026. The company reported -$0.007 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.056.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 116,128,160 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.007 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went up 5.342%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (435.71% Upside)
$6.00 (435.71% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $257.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
99.64%
12-Months-Change
Fundamentals
Return on Equity
-1292.68%
Trailing 12-Months
Asset Growth
-45.98%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$6.00
▲(435.71% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
Options Prices
Currently, No data available
---